First Opinion Mariana Socal How the drug price negotiation program could affect Medicare Part D beneficiaries
D.C. Diagnosis Rachel Cohrs STAT Plus: A new House health package & hospitals’ new site-neutral talking points
The Pharmalot View Ed Silverman STAT Plus: Why the drug industry’s opaque warnings on price negotiations fall short
First Opinion Arti K. Rai STAT Plus: What does ‘bona fide competition’ actually mean in the biologics market?
Politics Rachel Cohrs STAT Plus: House committees strike deal on health transparency, PBM reform package
Politics Rachel Cohrs STAT Plus: Astellas withdraws lawsuit after evading Medicare drug price negotiations
Politics Rachel Cohrs STAT Plus: The curious case of J&J’s Stelara, the unluckiest drug on Medicare’s list
Biotech Matthew Herper and Damian Garde STAT Plus: Winners and losers from Medicare’s list of drugs subject to price negotiation
Biotech Rachel Cohrs and Matthew Herper STAT Plus: Here are the 10 drugs that will be up first for Medicare price negotiation
Politics Rachel Cohrs STAT Plus: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
Hospitals Tara Bannow and Bob Herman STAT Plus: Medicare slashes safety net hospital payments on estimate that more people have insurance
Politics John Wilkerson STAT Plus: Medicare wants to improve Alzheimer’s care, but sidesteps drug prices
Pharmalot Ed Silverman and Rachel Cohrs Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
Politics John Wilkerson STAT Plus: Senate panel advances PBM reform — but sidesteps anything controversial
Politics Rachel Cohrs and John Wilkerson STAT Plus: Democrats already want to expand Medicare drug price negotiation
Politics Rachel Cohrs STAT Plus: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs
Politics Rachel Cohrs STAT Plus: Key House panel proposes lowering out-of-pocket drug costs in Medicare
Politics John Wilkerson STAT Plus: Bernie Sanders wants to replace drug patents with prizes for breakthrough medicines
Politics John Wilkerson STAT Plus: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change
Politics Rachel Cohrs STAT Plus: Conservative group opposing PBM reform spends record number on lobbying